Revvity down after Q3 revenue misses estimates

Shares of medical equipment maker Revvity RVTY.N fall 2.3% to $96.87 during market open

Co reports Q3 revenue of $699 mln, lower than analysts' estimates of $700.5 mln – LSEG data

Co reports Q3 adj. profit of $1.18/shr vs analysts' average estimate of $1.14/shr – LSEG data

RVTY reaffirms 2%–4% organic growth; raises annual adj. EPS forecast to $4.90-$5.00 from prior view of $4.85-$4.95

Board approves new $1 bln share buyback program, replacing prior plan, which was announced in October 2024

Including session's move, stock down 11.4% YTD